renal cell carcinoma

You have access
Investigating miRNA-related Pathways Contributing to Kidney Cancer Pathogenesis
PETER YOUSEF, RANIA IBRAHIM, CARL BOULOS, ZIYAD KHATAB, MARIA PASIC and ADRIANA KRIZOVA

Anticancer Research May 2022, 42 (5) 2355-2362; DOI: https://doi.org/10.21873/anticanres.15714
You have access
Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
SUGURU SHIROTAKE, YU MIYAMA, YASUTAKA BABA, HIROYUKI TAJIMA, YOSHITAKA OKADA, KEN NAKAZAWA, YOKO USAMI, MASANORI YASUDA, DAISUKE IGARASHI, GO KANEKO, KENT KANAO, MASAFUMI OYAMA and KOSHIRO NISHIMOTO

Anticancer Research May 2022, 42 (5) 2727-2735; DOI: https://doi.org/10.21873/anticanres.15751
You have access
Tumor Size Significantly Affects Prognosis in Pathological T3a Renal Cell Carcinoma
GU-SHUN LAI, JIAN-RI LI, SHIAN-SHIANG WANG, CHUAN-SHU CHEN, CHUN-KUANG YANG, SHENG-CHUN HUNG, CHEN-LI CHENG, YEN-CHUAN OU and KUN-YUAN CHIU

Anticancer Research April 2022, 42 (4) 2185-2191; DOI: https://doi.org/10.21873/anticanres.15701
You have access
SBRT in Localized Renal Carcinoma: A Review of the Literature
CAROLINA DE LA PINTA, RAQUEL GARCÍA LATORRE and RAQUEL FUENTES

Anticancer Research February 2022, 42 (2) 667-674; DOI: https://doi.org/10.21873/anticanres.15525
You have access
Prognostic Value of Copine 1 in Patients With Renal Cell Carcinoma
IMAN M. TALAAT, EMAN ABU-GHARBIEH, AMAL HUSSEIN, MAHMOOD HACHIM, ISRAA SOBHY, MOHAMED ELADL and WASEEM EL-HUNEIDI

Anticancer Research January 2022, 42 (1) 355-362; DOI: https://doi.org/10.21873/anticanres.15493
You have access
A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma
RENPEI KATO, TAKAHIRO KOJIMA, TOMOKAZU SAZUKA, HAYATO YAMAMOTO, SHOHEI FUKUDA, KAZUTOSHI YAMANA, YUSUKE SUGINO, SHUZO HAMAMOTO, NOBORU NAKAIGAWA, KOKI KABU, HIROSHI MURAKAMI and WATARU OBARA

Anticancer Research December 2021, 41 (12) 6199-6209; DOI: https://doi.org/10.21873/anticanres.15439
You have access
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA and MOTOHIDE UEMURA

Anticancer Research November 2021, 41 (11) 5811-5816; DOI: https://doi.org/10.21873/anticanres.15398
You have access
CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
YOHEI SEKINO, KENSHIRO TAKEMOTO, DAIKI MURATA, TAKASHI BABASAKI, KOHEI KOBATAKE, HIROYUKI KITANO, KENICHIRO IKEDA, KEISUKE GOTO, SHOGO INOUE, TETSUTARO HAYASHI, DAIKI TANIYAMA, MASANOBU SHIGETA, KAZUYA KURAOKA, KOJI MITA, MAYUMI KANEKO, KAZUHIRO SENTANI, NAOHIDE OUE and JUN TEISHIMA

Anticancer Research October 2021, 41 (10) 4875-4883; DOI: https://doi.org/10.21873/anticanres.15301
You have access
Clinical Significance of ¹⁸F-fluorodeoxyglucose and Glucose Transporter 1 mRNA in Clear Cell Renal Cell Carcinoma
HIRONORI BETSUNOH, SETSU SAKAMOTO, YASUSHI KAJI, AKINORI NUKUI, MINORU KOBAYASHI, MASAHIRO YASHI, KEITARO HAYASHI, NAOHIKO ANZAI and TAKAO KAMAI

Anticancer Research October 2021, 41 (10) 5179-5188; DOI: https://doi.org/10.21873/anticanres.15336
You have access
P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
YOHEI SEKINO, KENSHIRO TAKEMOTO, DAIKI MURATA, TAKASHI BABASAKI, KOHEI KOBATAKE, HIROYUKI KITANO, KENICHIRO IKEDA, KEISUKE GOTO, SHOGO INOUE, TETSUTARO HAYASHI, DAIKI TANIYAMA, MASANOBU SHIGETA, KAZUYA KURAOKA, KOJI MITA, MAYUMI KANEKO, KAZUHIRO SENTANI, NAOHIDE OUE and JUN TEISHIMA

Anticancer Research September 2021, 41 (9) 4287-4294; DOI: https://doi.org/10.21873/anticanres.15233

Main menu

User menu

Search

renal cell carcinoma

Pages